What the New WHO Guidelines Say
The WHO's first-ever comprehensive guidelines on childhood obesity management state that pharmacological treatments and bariatric surgery should not be used for children aged nine and under. This recommendation is a clear signal to healthcare providers
and parents to prioritise non-medical interventions for this young age group. The advice comes amid a sharp rise in childhood obesity, which has quadrupled since 1990, affecting an estimated 170 million children and adolescents. For older children, aged 10 to 19, the WHO allows for the conditional use of approved medicines, but only after a comprehensive lifestyle program has failed to yield results.
The 'Why' Behind the Warning
The primary reason for the WHO's cautious stance is the lack of robust, long-term data on the safety and efficacy of these potent drugs in young, developing bodies. There are significant concerns about how anti-obesity medications, such as GLP-1 agonists, could affect a child's growth, pubertal development, and overall health. Experts worry that the drastic calorie reduction caused by these drugs could lead to nutritional deficiencies at a critical stage of life. Furthermore, since obesity is a chronic condition, starting a child on medication so young raises questions about lifelong dependency and unknown long-term side effects. The WHO emphasises that the foundation of care must be a holistic approach, not a quick pharmaceutical fix.
The Indian Context: A Growing Concern
This global guidance is particularly relevant for India, which now ranks second in the world for the number of children living with high BMI. According to the World Obesity Atlas 2026, an estimated 41 million Indian children between 5 and 19 are affected by overweight or obesity. This alarming trend is driven by a combination of factors, including increased consumption of ultra-processed foods, more sedentary lifestyles tied to urbanisation, and a failure to meet recommended levels of physical activity. This health crisis is already leading to a rise in early-onset chronic conditions like hypertension and type 2 diabetes in younger populations.
The Recommended First Line of Defence
Instead of medication, the WHO strongly recommends a multi-pronged approach rooted in lifestyle modification. This includes structured interventions focused on healthy eating, increased physical activity, and behaviour-changing support for both the child and their family. The goal is to build sustainable habits. This can involve seeing a dietitian, creating a daily activity plan, reducing screen time, and ensuring the whole family adopts healthier practices. These lifestyle interventions remain the cornerstone of treatment and are considered the most effective and safest way to manage obesity in young children.
Prioritising Holistic Health Over a Pill
The WHO's directive serves as a crucial reminder that childhood obesity is a complex issue that cannot be solved with a prescription alone. While anti-obesity medications are being studied in children as young as six, the current evidence does not support their widespread use in the under-10 age group. The focus, according to global health experts, should be on creating supportive environments that foster healthy habits from a young age. This includes better nutrition in schools, safer spaces for play, and clear public health messaging that empowers families to make informed choices. The emphasis is on long-term health and well-being rather than just the number on a scale.
